A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy.

Trial Profile

A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Encenicline (Primary) ; Antipsychotics
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
    • 15 Jul 2015 According to FORUM Pharmaceuticals media release, results from this trial were published in the current online edition of the journal Neuropsychopharmacology.
    • 15 Jul 2015 Results published in FORUM Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top